Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 37 entries
View as:

A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

Phase: N/A Priority: Normal
NCT ID: NCT01991678 Org: User:
Start: 11/30/13 End: 09/30/17 Due: 09/30/18

A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain

Phase: N/A Priority: Normal
NCT ID: NCT01619839 Org: User:
Start: 06/30/12 End: 09/30/13 Due: 09/30/14

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00856375 Org: User:
Start: 12/31/08 End: 12/31/14 Due: 12/31/15

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05664217 Org: User:
Start: 12/23/22 End: 08/16/24 Due: 08/16/25

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Phase: N/A Priority: Normal
NCT ID: NCT06340360 Org: User:
Start: 04/02/24 End: 08/31/26 Due: 08/31/27

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00806156 Org: User:
Start: 10/31/08 End: 01/31/13 Due: 01/31/14

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Phase: N/A Priority: Normal
NCT ID: NCT01492101 Org: User:
Start: 12/31/11 End: 06/30/16 Due: 06/30/17

A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety

Phase: N/A Priority: Normal
NCT ID: NCT01976143 Org: User:
Start: 02/28/14 End: 09/30/16 Due: 09/30/17

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

Phase: N/A Priority: Normal
NCT ID: NCT04955262 Org: User:
Start: 08/31/19 End: 01/31/22 Due: 01/31/23

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

Phase: N/A Priority: Normal
NCT ID: NCT00598975 Org: User:
Start: 02/29/08 End: 12/31/11 Due: 12/31/12

Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain

Phase: N/A Priority: Normal
NCT ID: NCT02362672 Org: User:
Start: 03/11/15 End: 02/28/17 Due: 02/28/18

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04136756 Org: User:
Start: 10/07/19 End: 04/24/23 Due: 04/24/24

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

Phase: N/A Priority: Normal
NCT ID: NCT01457118 Org: User:
Start: 10/31/11 End: 11/30/17 Due: 11/30/18

A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02869295 Org: User:
Start: 12/31/15 End: 10/31/18 Due: 10/31/19

A Study of NKTR-358 (LY3471851) in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04380324 Org: User:
Start: 03/19/17 End: 01/20/19 Due: 01/20/20

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Phase: N/A Priority: Normal
NCT ID: NCT03729245 Org: User:
Start: 12/18/18 End: 10/19/22 Due: 10/19/23

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03785925 Org: User:
Start: 04/29/19 End: 06/30/22 Due: 06/30/23

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

Phase: N/A Priority: Normal
NCT ID: NCT04410445 Org: User:
Start: 07/27/20 End: 09/22/22 Due: 09/22/23

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT06136741 Org: User:
Start: 11/15/23 End: 12/31/26 Due: 12/31/27

A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.

Phase: N/A Priority: Normal
NCT ID: NCT03802227 Org: User:
Start: 10/22/18 End: 01/03/20 Due: 01/03/21

A Study of LY3471851 in Participants With Eczema

Phase: N/A Priority: Normal
NCT ID: NCT04081350 Org: User:
Start: 12/04/19 End: 06/24/22 Due: 06/24/23

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Phase: N/A Priority: Normal
NCT ID: NCT02915744 Org: User:
Start: 11/30/16 End: 07/31/20 Due: 07/31/21

A Phase I Study of LY3471851 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05565729 Org: User:
Start: 10/05/22 End: 02/23/23 Due: 02/23/24

Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03138889 Org: User:
Start: 06/09/17 End: 08/24/22 Due: 08/24/23

Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain

Phase: N/A Priority: Normal
NCT ID: NCT02367820 Org: User:
Start: 04/14/15 End: 01/31/18 Due: 01/31/19